100 results about "Shiga bacillus Dysentery" patented technology

The invention discloses a making method of short peptide to inhibit shigellosis with amino acid as list 1, which is characterized by the following: adding chemical group, amino acid, peptide, protein, PEG, marked material to N and C ends to do kinds of chemical or biological decoration; optimizing the stability or other applying property and using scale; fitting for treat shigellosis, enterorrhagia escherichia coli O157 and cholera vibrio.

A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus encompasses the Shiga toxoid or fragments thereof and the nucleic acid sequence of the Shiga toxoid or fragments thereof. The invention further encompasses the production of a Shiga toxoid, the production of antibodies using the Shiga toxoid and methods of productions, and an immunogenic composition containing the Shiga toxoid.

The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.

The present invention provides proteins comprising binding regions for cell-type specific targeting, Shiga toxin effector regions derived from A Subunits of members of the Shiga toxin family for providing Shiga toxin effector functions (e.g. cellular internalization and cytotoxicity), and carboxy-terminal endoplasmic reticulum localization signal motifs. The presently disclosed proteins can comprise additional exogenous materials, such as, e.g., antigens, cytotoxic agents, and detection-promoting agents, and are capable of targeted delivery of these additional exogenous materials into the interiors of target cells. The proteins of the present invention have uses in methods such as, e.g., methods involving targeted killing of target cells, delivering exogenous materials into target cells, labeling subcellular compartments of target cells, and diagnosing and/or treating a variety of conditions including cancers, tumors, other growth abnormalities, immune disorders, and microbial infections.

The invention belongs to the pharmaceutical biotechnology field, and relates to enterohemorrhagic E.coli O157:H7 Shiga toxin IIB epitope peptide and the application thereof. Four preferred polypeptides are derived from B-cell epitope of the subunit (Stx2A1) of EHEC O157:H7 Shiga toxin IIB epitope peptide. The product can be applied for preparing pharmaceuticals for the diagnosis and treatment of EHEC O157 infection and complications thereof.

The present invention provides protease-cleavage resistant molecules comprising Shiga toxin effector polypeptides capable of exhibiting potent, Shiga toxin functions (e.g. subcellular routing and cytotoxicity). The present invention also provides protease-cleavage resistant, cell-targeting molecules for targeting specific cell types, e.g., infected or malignant cells. Certain molecules of the present invention are cytotoxic, and certain cell-targeting molecules of the present invention may be used for the targeted killing of specific cell types and the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections. Certain cell-targeting molecules of the invention exhibit improved, in vivo tolerability as compared to related cell-targeted molecules comprising protease-cleavage sensitive, wild-type, Shiga toxin effector polypeptides. The cell-targeting molecules of the invention can deliver additional materials, such as, e.g., antigens, cytotoxic agents, and detection-promoting agents, into the interiors of target cells.

A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

The invention discloses a fusion protein SAmB as well as a coding gene and applications thereof. The fusion protein provided by the invention is named as SAmB, and comprises an A-subunit mutant protein of N-end II-type shiga toxin and a B-subunit protein of C-end I-type shiga toxin, wherein, the A-subunit mutant protein is a protein which mutates the active site amino acid residue of the A-subunit protein of the N-end II-type shiga toxin. The fusion protein SAmB provided by the invention can be used as a drug used for preventing and/or treating the shiga toxin pathogenic bacterial infection or infection complication.

The invention discloses a multiplex PCR detection method and kit for Shiga toxin-producing Escherichia coli and application thereof. The method and the kit thereof can simultaneously detect the genes consisting of stx1, stx2 and wzyO157 through a triplex PCR reaction, electrophoresis staining and ultraviolet visualization, subtypes consisting of stx1 and stx1c can be amplified by using a detection primer for the stx1 gene, subtypes consisting of stx2, stx2c and stx2d can be amplified by using a detection primer for the stx2 gene, and an O157 serotype strain can be identified by using a detection primer for the wzyO157 gene. According to the invention, the method and the kit can effectively detect stx and main variants thereof and can be used for distinguishing O157 from other non-O157 Escherichia coli, for directly detecting Shiga toxin-producing Escherichia coli in a food sample and for identifying a clinical strain and a food isolate.

The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.

The invention discloses a primer, a kit and a method for detecting bacillus coli shiga toxin through PSR (Polymerase Spiral Reaction) isothermal amplification reaction detection. The primer comprisesa detection primer Ft and a detection primer Bt, wherein a nucleotide sequence of the detection primer Ft is shown in SEQ ID NO.1; a nucleotide sequence of the detection primer Bt is shown in SEQ ID NO.2. The invention also provides a kit for detecting the bacillus coli shiga toxin through the PSR isothermal amplification reaction. The kit comprises the primers, BstDNA polymerase and a mixed solution of calcein and manganese chloride; detection of polymerase spiral reaction on the bacillus coli shiga toxin can be carried out, time loss and short time consumption cannot be caused by the changeof a temperature; a reaction process is simple and convenient, a detection period is short, the specificity is strong, and detection results can be observed by naked eyes. According to the primer, thekit and the method for detecting the bacillus coli shiga toxin through the PSR isothermal amplification reaction detection disclosed by the invention, significance on amplification development of a novel constant-temperature amplification technology and detection on site of microorganism can be achieved.

The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies.

The invention discloses primers, kit and method for detecting Escherichia coli Shiga toxin I by PSR (polymerase spiral reaction). The primers for detecting Escherichia coli Shiga toxin I are designedaccording to specific target sequence stx1 of Shiga toxin I and include detection primer Ft and detection primer Bt, as well as acceleration primer IF and acceleration primer IB, and their nucleotidesequences are shown as SEQ ID NO. 1 to 4. The invention also provides a kit for detecting Escherichia coli Shiga toxin I by PSR; the kit includes the above primers, Bst DNA polymerase, and a mixed solution of calcein and manganese chloride, is suitable for detecting Escherichia coli Shiga toxin I by polymerase spiral reaction; after developing with a fluorescent dye, the results can be judged witheyes. The kit is simple and quick to operate, low in detection cost and suitable for field detection.

The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition.

The invention relates to a monoclonal antibody and usage thereof, in particular to the monoclonal antibody of Shiga toxin II (StxII) and usage thereof, and belongs to the technical field of biopharming. The invention can obtain genes of heavy chain and light chain variable regions of the antibody from a hybridoma cell line S2C4 that can secrete anti-StxII monoclonal antibody with the PCR method clone, can express an ScFv antibody active segment with StxII protein specificity recognition by recombining two genes with genetic engineering methods, and can be used for preparing medicaments with EHEC infection and complicating diseases resistance. The monoclonal antibody has the advantages that the monoclonal antibody S2C4 has strong neutralizing activity not only to StxII protoxin but also to multiple StxII variants. Experiments prove that the monoclonal antibody S2C4 has wide neutralizing spectrum, can protect mice from the attack of StxII toxin and subtypes with lethal dosage, and is a medicament candidate with wide application prospect.

The invention discloses a polypeptide WA8 for inhibiting type-2 shiga toxin activity and a coding gene and application thereof. The polypeptide provided by the invention is named as WA8 (also named P8), and the amino acid sequence of the polypeptide is expressed as a sequence 2 in a sequence table. The polypeptide P8 can be prepared into a medicament for preventing and/or treating diseases caused by type-2 shiga toxin or pathogenic bacteria which can generate the type-2 shiga toxin.

The present invention provides compositions and methods for treating or preventing infection by shiga toxin producing bacteria.